The incidence of AEs related to LEN was not significantly different between the two groups. Results: The OS and PFS in the LEN-TACE group were significantly higher than those in the LEN monotherapy group ( p = 0.002 and p = 0.037, respectively).

In this study, at eight weeks after resumption of LEN after initial TACE, “deep response” was defined as achieving complete response or partial response (PR) on modified Response Evaluation Criteria in Solid Tumors (mRECIST), and at least a 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters as the reference. Additionally, we evaluated the tumor response, change in albumin-bilirubin (ALBI) score, factors affecting PFS and OS, and independent predictors contributing to the LEN-TACE sequential therapy deep response. We retrospectively compared the clinical outcomes, including overall survival (OS), progression-free survival (PFS), and incidence of adverse events (AEs), between the LEN-TACE and LEN monotherapy groups. Propensity score matching identified 63 matching pairs of patients with well-balanced characteristics. Methods: We enrolled a multicenter cohort of 247 patients with u-HCC treated with LEN between 20. We compared the efficacy and safety of LEN-TACE sequential therapy to LEN monotherapy and investigated the factors contributing to the LEN-TACE sequential therapy deep response.

Objective: There is limited information regarding the benefits of Lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for unresectable hepatocellular carcinoma (u-HCC).

Xlstat for hcc students